WSJ Tech News Briefing · Wednesday, September 23, 2026
Invida Biosciences, a company utilizing AI for early-stage drug discovery, has reportedly doubled its valuation to approximately $2 billion. The new funding will support Invida's progression into later-stage human trials for its experimental weight-loss maintenance pill and other drugs.
“The journal exclusively reports that Invida Biosciences, which uses the technology to streamline early stage drug discovery, has doubled its valuation to about $2 billion.”
“The financing will help Invida fund later stage human trials.”
“The company has an experimental daily pill designed to help patients maintain weight loss after discontinuing GLP1 medications and is also testing drugs for atopic dermatitis and inflammatory bowel disease.”